On the 25th, AstraZeneca Korea held an online press conference to commemorate the addition of Posiga (ingredient name dapagliflozin) for treatment of chronic heart failure, and the efficacy and clinical value of Posiga’s heart failure treatment confirmed through the DAPA-HF study. Introduced about.
The press conference was held by three members of the Korean Society of Heart Failure, chaired by Professor Dong-ju Choi (Department of Cardiology, Department of Cardiology, Bundang Seoul National University Hospital), and a relay lecture and discussion of three members who are in charge of research, academic and general affairs directors at the Korean Society of Heart Failure. The main topics were ▲Introduction of heart failure diseases and treatment goals ▲Possiga’s heart failure treatment effect and safety examined through the’DAPA-HF’ study ▲Management of comorbid diseases in heart failure patients.
The mortality rate of heart failure patients in Korea is fatal. According to domestic HF registry data, the mortality rate during hospitalization is as high as 6%, increasing to 10% after half a year, 20% after 2 years, and 30% after 4 years. In addition, cardiovascular disease risk remains even with standard treatment for heart failure, and 9 out of 10 patients still struggle with symptoms even with standard treatment.
Professor Jin-oh Choi said, “Despite standard treatment, the survival rate is low enough that more than half of the patients diagnosed with heart failure die within 5 years, and efforts are needed to further reduce the death and hospitalization rates due to heart failure and reduce medical costs.” He expressed his expectations for the option.
Prof. Sung-Hoon Choi said, “Among the results of the DAPA-HF study, it is the most meaningful part of this study to reduce the risk of death from worsening heart failure and cardiovascular disease in patients who are already receiving standard treatment for heart failure.” The potential value of the drug can be considered in that it has the effect of reducing not only death by death, but also total death.”
Prof. Sung-Hoon Choi said, “Based on these reasons, it is recommended to use SGLT-2 inhibitors preferentially in patients with cardiovascular disease or in high-risk patients in recent years. In particular, it is strongly recommended as a major drug to reduce death and readmission in HFrEF patients. There is” he explained.
He added, “In the future, changes in the current standard heart failure treatment are expected, and if the confirmed scientific results of dapaglogine are reflected in the field of actual first-line treatment, the health of Korean heart failure patients is expected to increase explosively in the future. In addition, it is expected to provide sufficient benefits in the health care sector of the country and society, including the family,” he added.
Professor Kim said, “As kidney function deteriorates in heart failure patients, the risk of hospitalization and death from heart failure also increases, so it is important to check kidney-related data in cardiology in terms of managing comorbid diseases,” he said.
Professor Choi Dong-ju said, “Because heart failure is a disease with a low survival rate, the emergence of new treatment options is of great significance.” If the results confirmed through Posiga’s clinical research are applied to the actual treatment environment, it will greatly improve the survival rate of heart failure patients in Korea. We are looking forward to making a contribution.”
Il Shim, Managing Director of the CVRM Division of AstraZeneca Korea said, “AstraZeneca proclaimed the vision’CaReMe (Cardiovascular, Renal, Metabolism)’ in 2018, which promotes an integrated approach to cardiovascular and renal endocrine diseases. We have been working steadily to resolve unmet demand and ultimately improve treatment outcomes and reduce mortality,” he said. “As the first SGLT-2 inhibitor to acquire the indication for chronic heart failure treatment, we hope that it can contribute to an innovative change in the heart failure treatment paradigm.” Revealed.